Screener
Halozyme Therapeutics HALO Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Research and development | 27,664 | 17,543 | 53,224 | 32,342 |
| Selling, general and administrative | 56,998 | 41,614 | 114,879 | 83,976 |
| Total operating expenses | 193,345 | 123,278 | 385,536 | 246,604 |
| Operating income | 287,654 | 202,441 | 472,171 | 343,976 |
| Other income (expense) | ||||
| Investment and other income, net | 2,836 | 6,891 | 4,154 | 13,709 |
| Interest expense | (5,588) | (4,394) | (11,096) | (8,919) |
| Income before income tax expense | 284,902 | 204,938 | 465,229 | 348,766 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's operating income?
- Halozyme Therapeutics (HALO) reported operating income of $287.65M in Q2 2026.
- How has Halozyme Therapeutics's operating income changed year-over-year?
- Halozyme Therapeutics's operating income increased by 42.1% year-over-year, from $202.44M to $287.65M.
- What is the long-term trend for Halozyme Therapeutics's operating income?
- Over 3 years (2021 to 2024), Halozyme Therapeutics's operating income has grown at a 26.0% compound annual growth rate (CAGR), from $275.9M to $551.48M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Halozyme Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude